

OA0 PHARMACY CHAIN 36.6 AND SUBSIDIARIES
CONSOLIDATED PROFIT AND LOSS STATEMENT
Q1 2009 ending 31 March 2009 (mln. rubles)

	Q1 2009	Q1 2008
Revenue	5 864.0	6 744.4
Cost of sales	(3 783.3)	(4 686.1)
Gross profit	2 080.7	2 058.2
Selling, general and administrative expenses	(2 001.1)	(2 230.3)
Impairment of goodwill	-	-
Operating income/loss	79.6	(172.0)
Finance costs	(301.1)	(267.5)
Other income (loss)	(8.4)	(2.0)
Foreign currency exchange gain (loss)	(328.3)	2.8
Income/(loss) before tax and investment activity	(558.1)	(438.8)
Gain on sale of investment	-	-
Income tax expense	10.4	(75.8)
Loss for the period	(648.5)	(588.3)
Attributable to:		
Minority interest	(100.8)	(73.6)

OAO PHARMACY CHAIN 36.6 AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEET
At 31 March 2009 (mln. rubles)

	Q1 2009	Q1 2008
ASSETS		
NON-CURRENT ASSETS:		
Property, plant & equipment	3 215.4	4 498.5
Goodwill	4 935.9	6 086.7
Intangible assets	280.4	297.3
Other assets	54.9	43.9
Total non-current assets	8 487	10 926
CURRENT ASSETS:		
Inventories	3 053.0	4 095.0
Accounts receivable	3 177.7	2 530.0
Other receivables and prepaid expenses	1 662.4	1 200.9
Cash and bank balances	766.4	804.6
Total current assets	8 659.6	8 630.5
TOTAL ASSETS	17 146.2	19 556.9
LIABILITIES AND SHAREHOLDERS' EQUITY		
SHAREHOLDERS' EQUITY:		
Share capital	6.0	6.0
Additional paid-in capital	2 796.1	2 796.1
Translation reserve	-	-
Retained earnings	(3 192.4)	(1 495.4)
Total shareholders' equity	(390.4)	1 306.7
MINORITY INTERESTS IN EQUITY OF SUBSIDIARIES		
LONG-TERM LIABILITIES:		
Borrowings	58.5	494.2
Share-based payment liability	-	23.6
Deferred tax liabilities	(4.8)	42.0
Long term lease payable	7.1	12.7
Total long-term liabilities	60.7	572.6
CURRENT LIABILITIES:		
Accounts payable	6 120.6	5 543.2
Borrowings	4 779.8	6 261.5
Other payables and accrued expenses	1 273.3	1 390.3
Taxes payable	527.8	613.7
Current portion of share-based payments liability	(0)	32.5
Current portion of lease payable	32.0	47.4
Total current liabilities	12 733.4	13 888.7
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	17 146.2	19 556.9

OA0 PHARMACY CHAIN 36.6 AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF CASH FLOWS
At 31 March 2009 (mln. rubles)

	Q1 2009	Q1 2008
OPERATING ACTIVITIES		
Income/loss before taxation and minority interest	(558.1)	(438.8)
Gain on sale of investment	-	-
Depreciation and amortization	132.1	152.6
Loss on sale of securities	-	-
Loss on disposal of property, plan and equipment and unrealized investments	-	-
Profit on disposal of subsidiary	-	-
Impairment recognized (reversed) on accounts receivable	(1.1)	(27.9)
Unused vacation provision	23.4	27.0
Inventory provision and write-off	44.8	49.9
Other	-	-
Impairment of goodwill	-	-
Share based payments expenses	-	3.0
Foreign exchange loss/(gain)	328.3	(2.8)
Finance costs	301.1	267.5
Operating cash flow before working capital changes	270.5	30.5
Increase in inventories	(210.6)	(82.4)
Increase in accounts receivable	127.6	(26.3)
Increase in other receivables and prepaid expenses	86.7	4.5
Increase in accounts payable	50.2	805.2
Increase in other payables and accruals	(241.4)	(36.6)
Cash generated from operations	83.0	694.9
Income taxes paid	(87.9)	(67.1)
Finance costs paid	(177.1)	(94.5)
Net cash generated by (used in) operating activities	(181.9)	533.4
INVESTING ACTIVITIES		
Net cash outflow on acquisition of subsidiaries	-	(100.1)
Purchase of property, plant and equipment	(21.4)	(36.2)
Purchase of intangible assets	(3.4)	7.7
Proceeds from sale of property, plant and equipment	-	-
Proceeds from partial disposal of subsidiary	-	-
Proceeds from disposal of subsidiaries, net of cash disposed	-	-
Net cash generated by (used in) investing activities	(24.8)	(128.6)
FINANCING ACTIVITIES		
Proceeds from borrowings	270.7	(411.4)
Repayments of borrowings	-	-
Proceeds from issuance of ordinary shares, net	-	-
Proceeds from consortium of investors	-	-
Distributions paid to minority shareholders	-	-
Net cash (used in) generated by financing activities	270.7	(411.4)
Effect of translation to presentation currency	-	-
Net (decrease) increase in cash and cash equivalents	63.9	(6.5)
Cash and cash equivalents at beginning of the period	702.4	807.2
Cash and cash equivalents at end of the period	766.4	800.7